Second cohort in Aptahem’s FIH study performed and approved by the ethics committee
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the second dose cohort in the clinical First in Human (FIH) study in healthy volunteers has been performed and approved by the Dutch ethics committee.The purpose of the study is to evaluate safety and tolerability of Apta-1 in various doses. As previously communicated, the second dose cohort was initiated in early January 2023 and has now been finalized and approved by the authority. Apta-1 seems to continue to be safe and well tolerated